Lucknow, India

Sarvesh Kumar Verma

This inventor holds 1 USPTO granted patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2026.


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sarvesh Kumar Verma: Innovator in Prostate Health Solutions

Introduction

Sarvesh Kumar Verma is a notable inventor based in Lucknow, India. He has made significant contributions to the field of medical science, particularly in the management of benign prostatic hyperplasia (BPH). His innovative approach to treatment showcases his dedication to improving health outcomes.

Latest Patents

Sarvesh Kumar Verma holds a patent for "Chebulinic acid and its enriched fraction from the fruits for treatment of benign prostatic hyperplasia (BPH) and its preparation thereof." This invention highlights the beneficial effects of Chebulinic acid (CA) and its enriched standardized fraction (CAEF) isolated from specific fruits. The patent outlines a novel and economically viable method for isolating Chebulinic acid and ellagic acid from dried and powdered fruits without the need for expensive chromatographic techniques.

Career Highlights

Sarvesh Kumar Verma is associated with the Council of Scientific and Industrial Research, where he has been instrumental in advancing research in medicinal compounds. His work emphasizes the importance of accessible and effective treatments for common health issues.

Collaborations

He has collaborated with notable colleagues, including Narender Tadigoppula and Monika Sachdev, to further enhance the impact of his research and innovations.

Conclusion

Sarvesh Kumar Verma's contributions to the field of medicine, particularly through his patent on Chebulinic acid, demonstrate his commitment to innovation and health improvement. His work continues to inspire advancements in the treatment of benign prostatic hyperplasia.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…